Skip to main
CNTX
CNTX logo

CNTX Stock Forecast & Price Target

CNTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Context Therapeutics Inc. is advancing its clinical program for CTIM-76, a promising bispecific antibody targeting CLDN6, which has shown early signs of clinical activity and safety in preliminary data, supporting ongoing trials in multiple solid tumor types. The company’s strong cash position, projected to last into 2027, enables it to navigate through upcoming clinical and regulatory milestones, attracting potential partners and increasing investor interest ahead of traditional efficacy results. A favorable comparison to competitors’ assets in terms of potency and selectivity strengthens the outlook for CTIM-76, with the potential for substantial valuation impact from further clinical developments.

Bears say

Context Therapeutics Inc's financial outlook is negatively impacted by several key factors, including a reported net loss of $9.7 million for Q3 2025, despite a significant reduction in research and development (R&D) expenses from $16.8 million to $8.7 million. Additionally, the company's ability to secure future financing appears precarious, with an estimated need for approximately $250 million by 2041, while only having a cash runway extending into 2027. The presence of various risks related to safety, efficacy, and regulatory concerns further compound the uncertainty surrounding Context's clinical and preclinical programs, potentially undermining investor confidence.

CNTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Context Therapeutics LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Context Therapeutics LLC (CNTX) Forecast

Analysts have given CNTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, CNTX has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Context Therapeutics LLC (CNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.